Cyclotron and Nanotechnology: A Systematic Review of Synergistic Advances in Cancer Therapeutics and Theranostics
Keywords:
Biodistribution, Cyclotron, Cancer therapy, Imaging, Nanoparticles, Nanotechnology, personalized medicine, Radiopharmaceuticals, Radioisotopes, Synergistic therapy, Theranostics, Targeted drug delivery, Tumor targetingAbstract
Cancer continues to be a leading global health concern, with current therapies often facing limitations in efficacy and severe side effects. The combination of cyclotron technology, which is used to produce radioisotopes for imaging and therapy, and nanotechnology, with its potential for precise drug delivery and theranostics, offers a promising solution for more effective and targeted cancer treatment. This systematic review seeks to assess and consolidate existing evidence on the integration of cyclotron-generated radioisotopes and nanotechnology in the treatment of cancer. The review specifically explores their roles in cancer imaging, therapy, and theranostics, and investigates the synergistic benefits of combining these technologies for more targeted and personalized treatment. A comprehensive search was performed across databases including PubMed, Scopus, and Web of Science, utilizing keywords such as “cyclotron,” “nanotechnology,” “cancer treatment,” and “radiopharmaceuticals.” Studies published within the last decade focused on experimental, preclinical, or clinical research combining cyclotron-based radioisotopes and nanotechnology were included. Non-cancer-related studies and those without sufficient data on synergistic effects were excluded. The review identifies various radioisotopes such as 68Ga, 18F, and 177Lu, commonly used in imaging and therapy, and highlights advancements in nanotechnology including liposomes and dendrimers. The synergy between these technologies enhances tumor targeting, improves biodistribution, and reduces side effects. However, challenges remain, including the high cost of radioisotope production and scalability of nanoparticle formulations. The integration of cyclotron-produced radioisotopes and nanotechnology represents a promising strategy for cancer treatment. Overcoming challenges like cost and scalability, and advancing clinical applications, will be critical for the success of this approach in future cancer therapies.
References
World Health Organization. Cancer fact sheet. 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020; 70(1):7-30. https://doi.org/10.3322/ caac.21590
Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next Generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013
Qaim SM. Cyclotron Production of Medical Radionuclides. Springer eBooks. 2011; 1903–33. https://link.springer.com/referenceworkentry/10.1007/978-1-4419-0720-2_39
Crișan G, Moldovean-Cioroianu NS, Timaru DG, Andrieș G, Căinap C, Chiș V. Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int. J. Mol. Sci. 2022; 23(9):5023. https://doi.org/10.3390/ijms23095023
Ali S, Tyagi A, Bae H. Ionomic approaches for discovery of novel stress-resilient genes in plants. Int. J. Mol. Sci. 2021;22(13):7182. Available from: https://doi.org/10.3390%2Fijms22137182
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. In: Nano-enabled medical applications. 2020:61–91. https://doi.org/10.1201/9780429399039
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer Nano medicine: progress, challenges and opportunities. Nat. Rev. Cancer. 2017; 17(1):20-37. https://www.nature.com/articles/nrc.2016.108
Wang X, Yang L, Chen Z, Shin DM. Application of Nanotechnology in Cancer Therapy and Imaging. CA: Cancer. J. Clin. 2008; 58(2):97–110. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/CA.2007.0003
Jia L, Zhang P, Sun H, Dai Y, Liang S, Bai X, et al. Optimization of nanoparticles for smart drug delivery: a review. Nanomaterials. 2021; 11(11):2790. https://doi.org/10.3390/nano11112790
Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug. Discov. Today. 2012;17(17-18):1044–52. https://doi.org/10.1016/j.drudis.2012.05.010
Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Frontiers in Bioengineering and Biotechnology. 2023; 11. https://doi.org/10.3389/fbioe.2023.1177151
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339(339): b2700–0. Available from: https://www.bmj.com/content/339/bmj.b2700
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement. PLoS Medicine. 2009;6(7). https://doi.org/10.1371/journal.pmed.1000097
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928. https://doi.org/10.1136/bmj.d5928
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71
Khan K, Kunz R, Kleijnen J, Antes G. Systematic reviews to support evidence-based medicine. 3rd ed. Crc press; 2011 Feb 25.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366(1): l4898. Available from: https://www.bmj.com/content/366/bmj.l4898
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R. Radiotheranostics: a roadmap for future development. Lancet. Oncol. 2020; 21(3): e146-56. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30821-6/abstract
Dash A, Pillai MR, Knapp FF. Production of 177 Lu for targeted radionuclide therapy: available options. Eur. J. Nucl. Med. Mol. Imaging. 2015; 49:85-107. Available from: https://link.springer.com/article/10.1007/s13139-014-0315-z
Rösch F. Past, present and future of 68Ge/68Ga generators. Appl. Radiat. Isot. 2013; 76:24–30. https://doi.org/10.1016/j.apradiso.2012.10.012
Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J. Control. Release. 2012;160(2):117-34. https://doi.org/10.1016/j.jconrel.2012.03.020
Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine—challenge and perspectives. Angewandte Chemie International Edition. 2009;48(5):872-97. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175737/
Kashyap BK, Singh V, Solanki MK, Kumar A, Ruokolainen J. Smart Nanomaterials in cancer theranostics: challenges and opportunities. ACS omega. 2023; 8(16):14290–320. https://pubs.acs.org/doi/10.1021/acsomega.2c07840
Sun N, Wang T, Zhang S. Radionuclide-labelled nanoparticles for cancer combination therapy: a review. J Nanobiotechnol. 2024; 22(1). https://doi.org/10.1186/s12951-024-03020-3
Huang X, Jain PK, El-Sayed IH, El-Sayed MA. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine. 2007; 2(5):681–93. https://doi.org/10.2217/17435889.2.5.681
Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal. Transduct. Target. Ther. 2021; 6(1):254. https://doi.org/10.1038/s41392-021-00648-7
Carrese B, Sanità G, Lamberti A. Nanoparticles Design for Theranostic Approach in Cancer Disease. Cancers (Basel). 2022; 14(19):4654. https://doi.org/10.3390/cancers14194654
Long NV, Yang Y, Teranishi T, Thi CM, Cao Y, Nogami M. Biomedical Applications of Advanced Multifunctional Magnetic Nanoparticles. J. Nanosci. Nanotechnol. 2015; 15(12):10091-107. https://doi.org/10.1166/jnn.2015.11691
Zhen Z, Tang W, Chuang YJ, et al. Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS Nano. 2014; 8(6):6004–13. https://pubs.acs.org/doi/10.1021/nn501134q
Bhuniya S, Maiti S, Kim EJ, et al. An activatable theranostic for targeted cancer therapy and imaging. Angew. Chem. Int. Ed. Engl. 2014;53(17):4469–4474. https://doi.org/10.1002/anie.201311133
